[Fertility sparing treatment of endometrial carcinoma]

Ned Tijdschr Geneeskd. 2021 Nov 25:165:D5765.
[Article in Dutch]

Abstract

Background: The incidence of endometrial carcinoma (EC) is rising worldwide due to an increased life expectancy and obesity. Approximately 2% of patients with EC is under the age of 45. Because the incidence is also rising in young women, there is a clinical need for safe fertility sparing alternative treatments.

Case description: A 32-year-old women was diagnosed with low-grade endometrioid EC. Hysteroscopic tumour resection and progestin treatment resulted in complete tumour regression. The patient became pregnant through in vitro fertilisation (IVF).

Conclusion: This case illustrates that fertility sparing treatment, with oral progestin treatment is an alternative treatment option in selected young women with low grade, early stage endometrial carcinoma to achieve pregnancy. This treatment is internationally accepted.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Endometrial Hyperplasia* / drug therapy
  • Endometrial Hyperplasia* / surgery
  • Endometrial Neoplasms* / drug therapy
  • Endometrial Neoplasms* / surgery
  • Female
  • Fertility Preservation* / methods
  • Humans
  • Pregnancy
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal